Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

A surge in respiratory illness is typical for this time of year, and the simultaneous outbreak of highly contagious norovirus is piling on to the public health risk. Commonly known as stomach flu, ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...